Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS
29. Februar 2024 07:00 ET
|
Coave Therapeutics
CTx-TFEB is a novel, targeted genetic medicine approach designed to promote autophagy and reduce the accumulation of toxic protein aggregates in neurons Funding aims to support the progression of...
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
06. Dezember 2023 16:08 ET
|
Wave Life Sciences USA, Inc.
Wave Life Sciences Announces Initiation of Dosing in Clinical Trial Evaluating First-Ever RNA Editing Candidate, WVE-006, in Alpha-1 Antitrypsin Deficiency
FDA approves muscular dystrophy drug built on Children’s National research
27. Oktober 2023 09:27 ET
|
Children's National Hospital
WASHINGTON, D.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration’s approval...
Coave Therapeutics to Present at Upcoming Conferences
28. September 2023 08:15 ET
|
Coave Therapeutics
Paris, France, September 28, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
Muscular Dystrophy Association Celebrates FDA Approval of Sarepta Therapeutics’ ELEVIDYS for Treatment of Duchenne Muscular Dystrophy
22. Juni 2023 15:31 ET
|
Muscular Dystrophy Association
New York, June 22, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene...
Muscular Dystrophy Association Announces Gene Therapy Support Network for Families Living with Neuromuscular Disease
22. Mai 2023 14:48 ET
|
Muscular Dystrophy Association
New York, May 22, 2023 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) announced today the launch of the MDA Gene Therapy Support Network (GTx), ahead of a pending FDA approval for the...
Muscular Dystrophy Association Announces Nearly $400K in Research Grants to Address Challenges in Duchenne Muscular Dystrophy Gene Therapy
13. März 2023 09:00 ET
|
Muscular Dystrophy Association
New York, NY, March 13, 2023 (GLOBE NEWSWIRE) -- Today, Muscular Dystrophy Association (MDA) announced two research grants designed to address potential transgene-triggered safety concerns in...
Gennao Bio Appoints Chris Duke as Chief Operating Officer and Julie Hambleton, M.D., to Board of Directors
13. Juli 2021 07:30 ET
|
Gennao Bio
HOPEWELL, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the...
Gennao Bio Closes $40 Million Series A Financing to Develop Pipeline of Targeted Nucleic Acid Therapeutics
10. Mai 2021 08:30 ET
|
Gennao Bio
~ Financing Co-led by OrbiMed and Logos Capital to Support Advancement of Proprietary Gene Monoclonal Antibody Platform (GMAB) ~ ~ Stephen Squinto, Ph.D., Appointed Chief Executive Officer and...